# A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

> **NCT04585776** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 31 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** LY900014
- **DRUG:** Insulin Degludec

## Key facts

- **NCT ID:** NCT04585776
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-30
- **Primary completion:** 2021-05-27
- **Final completion:** 2021-05-27
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04585776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04585776, "A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04585776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*